Here, we report that elevated oncofetal CS expression predicts poor disease-free and overall survival in four independent patient cohorts of early-stage NSCLC (n = 493), independent of KRAS and EGFR mutations. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.